HIV Microelisa System
- FOB Price:Get Latest Price >
- Min.Order:10 Box(es)
- Production Capacity:In stock
- Payment Terms:T/T
- Favorite
Business Type:Manufacturer
Country/Region:China
Ddu Verified
HOT Rank
6/10
AVIOQ INC.
Vioq, Inc., founded in 2007 and incorporated in North Carolina, has headquarters in Research Triangle Park, NC. The Management Team is comprised of 9 individuals (6 PhDs) with over 250 years of experience in the diagnostics industry. The company’s current products include an FDA approved HIV-1 assay (a Class III device), an FDA licensed HTLV-I/II assay for screening serum and plasma from blood donor, and cadaveric samples, which also has CE marking and Health Canada approval. In addition, three other products with CE marking including a homogeneous biochemiluminescence based Flu A/B diagnosis test, a rapid influenza virus drug resistance test and an Oral fluid collection device. The company has two other HIV products in final development; a 4th Gen HIV-1/2/Ag test and an HIV Profile assay for the detection and estimation of antibody levels directed to different gene products of HIV-1 and HIV-2.
Our manufacturing facility is FDA (BLA) licensed and ISO 13485 certified. Bio-manufacturing and analytical capabilities include production of antigens produced either in mammalian or bacterial cells, monoclonal antibodies produced in hybridomas, and viral lysates/virus produced from large-scale cell cultures.Our R&D facility is fully-equipped with modern laboratory spaces. As a result, our R&D team, along with our teams in manufacturing, quality assurance and regulatory, have ample experience in all phases of IVD product development, starting from raw material development and finishing with an FDA approved and/or CE marked IVD.
Search for Critical Care Products’ Application Specialist
Who Are We
A worldwide leading group, developing and manufacturing IVD (In Vitro Diagnostics) products.
The Group overall turnover exceeded 1.026 Million Euros in 2013. Today the Group has a direct presence in more than 24 countries world-wide actually distributing products, through partners, in more than 62 countries. In its continued growth and effort to deliver to its Distributors and End Users a better service the company is looking for a Critical Care(Blood Gas) Application Specialist to be based at its Representative Office in Bangkok, Thailand.
The Representative Office is established to provide support to the following territories: Thailand, Philippines, Viet Nam, Myanmar, Laos, Cambodia, Malaysia, Singapore, Indonesia and Brunei.
Business Type:Manufacturer
Country/Region:China
Ddu Verified
HOT Rank
6/10
FDA Approved for
>Serum >Oral Fluid
>Plasma >Dired blood spot
Proven HIV Whole Viral Lysate antigens +native gb160
Detects lgG& lgM Antibodies
High Cross reactivity with HIV-2
The AVIOQ HIV-1Mircoelisa System uses inactivated, purified HIV-1 antigens, which are coated on the wells of microwell plates, for the detection of antibodies against HIV-1.
>100% specificity in random donor population seen in clinical trials (95% confidence interval of 99.94% to 100%)
Result: Reduced costs for confirmatory testing
>High positive predictive value
Result: Saves the cost of running unnecessary Western Blot tests.
>Fast ,convenient procedure;total incubation time only 2hours 10 minutes.
Result: Practical 60/60/10 minute formate adapts to laboratory workflow with rapid throughput to results
>Direct dilution into mircoplate well
Result:Eliminates need for time-consuming external dilution step and cost of dilution tubes
>Economical and versatile 8-well strip plate format
Result: Adaptable to automation
>Convenient microelisa procedure
Result: Color-coded reagents with sample addition monitor for confidence in results
>High correlation between initial and repeat results
Result: Reduces unnecessary repeat testing